January 28, 2020

Alexandria, Va. – The American Society of Clinical Oncology (ASCO) released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” summarizing the Society’s concerns about the potential negative impact that recent proposals to establish annual limits on federal funding for Medicaid—or block grants—could have on patients with cancer. The statement urges state and federal policymakers not to enact, apply for, or advance any proposals to establish block grants for Medicaid programs. 

January 24, 2020

SAN FRANCISCO - Positive findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study cohorts on the potential benefit of various molecularly targeted drugs in patients with advanced colorectal cancer will be presented at the 2020 Gastrointestinal Cancers Symposium, taking place January 23-25, 2020 at the Moscone West Building in San Francisco, California.

January 23, 2020

Statement by ASCO President Howard A. "Skip" Burris III, MD, FACP, FASCO, applauding the Surgeon General for releasing its first report on smoking cessation in 30 years. 

January 21, 2020

ALEXANDRIA, Va. – Patient-reported outcomes from two large studies show that quality of life is maintained longer with newer drug combinations compared with standard of care for the treatment of patients with a specific type of colorectal cancer and unresectable hepatocellular carcinoma. The results will be presented at the 2020 Gastrointestinal Cancers Symposium, taking place January 23-25 in San Francisco, California.

January 21, 2020

ALEXANDRIA, Va. – A retrospective analysis of 26,768 young adults age 40 and under found that those who live in areas with lower income (less than $38,000) and lower education (under 79% high school graduation rate), as well as those who live in urban areas, had worse outcomes and a higher risk of death. The results will be presented at the 2020 Gastrointestinal Cancers Symposium, taking place January 23-25 in San Francisco, California.

Each year more than 16,000 people under age 50 are diagnosed with colorectal cancer in the United States, and incidence rates among this population have risen 51% since 1994 with the sharpest increase among those age 20 to 29[1]

“There are a lot of disparities in health care,” said lead author, Ashley Matusz-Fisher, MD, Levine Cancer Institute, Charlotte, NC. “It is important to look at the sociodemographic disparities so that we can learn more and try to eliminate them.”


[1] JNCI: Journal of the National Cancer Institute, Volume 109, Issue 8, August 2017, djw322, https://doi.org/10.1093/jnci/djw322

January 21, 2020

ALEXANDRIA, Va. – A blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal (GI) cancers that could potentially help detect cancer at earlier stages will be presented 2020 Gastrointestinal Cancers Symposium, taking place January 23-25 in San Francisco, California.

“The potential of this test is to diagnose cancer earlier, when it’s more treatable. The ability to do that across cancer types could be quite valuable. Many of the cancer types that this test detects don’t currently have screening tests that allow earlier cancer detection before the cancers cause symptoms,” said lead investigator Brian M. Wolpin, MD, MPH, who is Director of the Gastrointestinal Cancer Center and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute in Boston.

In general, GI cancers are difficult to identify early. The GI organs are deep inside the body, so small tumors can’t easily be seen or felt during routine physical exams. No screening tests are available for cancers like gallbladder, bile duct, and pancreatic cancer. Screening exams do exist for other types of GI cancers, such as colorectal and stomach cancer, but many of these tests are invasive. When GI cancers are diagnosed, they are often at advanced stages that are more difficult to treat. An accurate test based on a simple blood sample could lead to earlier diagnosis for GI cancers.

December 19, 2019

ASCO applauds Congress for working across party lines to raise the minimum age for purchasing tobacco products to 21 and for continuing its commitment to investing in our nation's biomedical research infrastructure.

December 18, 2019

Ten oncology practices from rural and urban centers in the U.S. that primarily treat underserved populations have received grant funding to participate in the American Society of Clinical Oncology’s (ASCO) Quality Oncology Practice Initiative (QOPI®) and Quality Training Program. ASCO announced today the recipients of the grants, which are supported by the Stavros Niarchos Foundation.

December 17, 2019

ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) has elected Everett E. Vokes, MD, FASCO, a long-time member and volunteer, to serve as its President for the term beginning in June 2021. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2020. Six new members were also elected to the ASCO Board of Directors and Nominating Committee. 

December 12, 2019

"The American Society of Clinical Oncology (ASCO) congratulates Stephen M. Hahn, MD, FASTRO, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA). 

"An oncologist with more than 30 years of experience providing direct patient care, Dr. Hahn understands how critical it is for Americans living with cancer to have access to innovative drugs and medical devices that safely and effectively diagnose, treat, manage, and cure their disease. 

November 26, 2019

The American Society of Clinical Oncology (ASCO) released today a major update to its Patient-Centered Oncology Payment (PCOP) model, an alternative payment model designed to support transformation in cancer care delivery and reimbursement while ensuring that patients with cancer have access to high-quality, high-value care. The updated model reflects lessons learned from previous demonstration programs, including a PCOP pilot in New Mexico.

November 14, 2019

Two science-based organizations, CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology, and the American Heart Association, the leading voluntary health organization devoted to a world of longer, healthier lives, are teaming up to make oncology datasets from the CancerLinQ Discovery® database available to academic researchers, non-profits, health care providers and government agencies through a customized version of the American Heart Association’s Precision Medicine Platform.

November 7, 2019

Twenty-Four practices in two countries elevated their standard of care and achieved the American Society of Clinical Oncology's (ASCO) Quality Oncology Practice Initiative (QOPI®) Certification in the third quarter of this year. 

November 6, 2019

Medical oncologists in Brazil are being encouraged to take advantage of a new measure set for assessing the quality of care they provide to patients with lung cancer through a collaboration between the International Association for the Study of Lung Cancer (IASLC) and ASCO. 

November 1, 2019

“The American Society of Clinical Oncology (ASCO) congratulates Stephen M. Hahn, MD, FASTRO, on his nomination by President Trump to serve as the next Commissioner of the Food and Drug Administration (FDA). An oncologist and long-time member of ASCO, Dr. Hahn currently serves as the Chief Medical Executive at The University of Texas MD Anderson Cancer Center. He has a strong grasp of the drug development process and understands the realities of working in a complex clinical care environment at one of the largest cancer centers in the world.